| ADCC | Antibody-dependent cell cytotoxicity |
| APCs | Antigen-presenting cells |
| BLM | Bleomycin |
| Ca2+ | Calcium |
| CisPt | Cisplatin |
| CRT | Chemoradiotherapy |
| CSCs | Cancer stem cells |
| DAMPs | Damage-associated molecular patterns |
| ECT | Electrochemotherapy |
| EFPs | Electrical field pulses |
| EMA | European Medicines Agency |
| EP | Electroporation |
| EPR | Enhanced permeability and retention effect |
| ER | Endoplasmic reticulum |
| FDA | U.S. Food and Drug Administration |
| FU | 5- fluorouracil |
| GA | General anesthesia |
| GE | Gene electroporation |
| Gy | Gray |
| H&N | Head and neck |
| HNSCC | Head-and-neck squamous cell carcinoma |
| HPV | Human papillomavirus |
| K | Dielectric constant |
| IL | Interleukin |
| I.T. | Intra-tumor |
| I.V. | Intra-venous |
| LA | Local anesthesia |
| MCAM | Melanoma cell adhesion molecule |
| NMs | Nanomaterial |
| NV | Nanovector |
| NsEFPs | Nanosecond electrical field pulses |
| OS | Overall survival |
| PCs | Protein coronas |
| PD-L1 | Programmed death ligand 1 |
| PEG | poly-(ethylene glycol) |
| QoL | Quality of life |
| RB1 | Retinoblastoma-associated protein |
| RT | Radiotherapy |
| SOP | Standard operating procedure |
| SR | Sarcoplasmic reticulum |
| TMP | Transmembrane potential |
| Vm | Transmembrane voltage |